Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver

[1]  Lena Eliasson,et al.  Whole-Genome Bisulfite Sequencing of Human Pancreatic Islets Reveals Novel Differentially Methylated Regions in Type 2 Diabetes Pathogenesis , 2017, Diabetes.

[2]  C. Molony,et al.  Genomic Characterization of Metformin Hepatic Response , 2016, PLoS genetics.

[3]  H. Taylor,et al.  Metformin alters DNA methylation genome-wide via the H19/SAHH axis , 2016, Oncogene.

[4]  Xing Fu,et al.  AMPK/α-Ketoglutarate Axis Dynamically Mediates DNA Demethylation in the Prdm16 Promoter and Brown Adipogenesis. , 2016, Cell metabolism.

[5]  Allan Vaag,et al.  Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes , 2016, Nature Communications.

[6]  C. Ling,et al.  Epigenetic Alterations in Human Liver From Subjects With Type 2 Diabetes in Parallel With Reduced Folate Levels. , 2015, The Journal of clinical endocrinology and metabolism.

[7]  J. Pihlajamäki,et al.  Persistent organic pollutants and non-alcoholic fatty liver disease in morbidly obese patients: a cohort study , 2015, Environmental Health.

[8]  K. Giacomini,et al.  Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin , 2015, Molecular Pharmacology.

[9]  C. Palmer,et al.  Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study , 2014, Diabetes.

[10]  P. Soininen,et al.  Lipoprotein subclass metabolism in nonalcoholic steatohepatitis[S] , 2014, Journal of Lipid Research.

[11]  B. Bao,et al.  Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. , 2014, Annals of translational medicine.

[12]  C. Ling,et al.  Altered DNA Methylation and Differential Expression of Genes Influencing Metabolism and Inflammation in Adipose Tissue From Subjects With Type 2 Diabetes , 2014, Diabetes.

[13]  Jose C Florez,et al.  An update on the pharmacogenomics of metformin: progress, problems and potential. , 2014, Pharmacogenomics.

[14]  C. Ling,et al.  Genome-Wide DNA Methylation Analysis of Human Pancreatic Islets from Type 2 Diabetic and Non-Diabetic Donors Identifies Candidate Genes That Influence Insulin Secretion , 2014, PLoS genetics.

[15]  James R. Wagner,et al.  The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts , 2014, Genome Biology.

[16]  M. Laakso,et al.  Adipose tissue INSR splicing in humans associates with fasting insulin level and is regulated by weight loss , 2014, Diabetologia.

[17]  R. Schwenk,et al.  Genetic and epigenetic control of metabolic health. , 2013, Molecular metabolism.

[18]  Yi Zhang,et al.  TET enzymes, TDG and the dynamics of DNA demethylation , 2013, Nature.

[19]  M. Kals,et al.  Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function , 2013, Genome Biology.

[20]  S. Masuda,et al.  Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin‐induced lactic acidosis , 2012, British journal of pharmacology.

[21]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[22]  T. Terasaki,et al.  Absolute Quantification and Differential Expression of Drug Transporters, Cytochrome P450 Enzymes, and UDP-Glucuronosyltransferases in Cultured Primary Human Hepatocytes , 2012, Drug Metabolism and Disposition.

[23]  Ute Hofmann,et al.  DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma , 2011, Genome Medicine.

[24]  T. Ferrin,et al.  Genetic and Epigenetic Regulation of the Organic Cation Transporter 3, SLC22A3 , 2011, The Pharmacogenomics Journal.

[25]  B. Viollet,et al.  Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status , 2011, Diabetologia.

[26]  Alan R. Shuldiner,et al.  Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program , 2010, Diabetes.

[27]  B. Martín-Castillo,et al.  Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena , 2010, Cell cycle.

[28]  D. Keppler,et al.  Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.

[29]  T. Mizuno,et al.  Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin , 2009, Molecular Pharmacology.

[30]  M. McCarthy,et al.  Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study , 2009, Diabetes.

[31]  Matthijs L. Becker,et al.  Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study , 2009, Diabetes.

[32]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[33]  Hiroshi Omote,et al.  A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Yuichi Sugiyama,et al.  Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.